Imidazolylethanamide of pentanedioic acid (Acidi pentandioici imidazolylaethanamidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Stimulators of hematopoiesis

Included in the formulation
  • Ingavirin®
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Ingavirin®
    capsules inwards 
    VALENTA PHARM, PAO     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    ONLS

    VED

    АТХ:

    J.05.A.X   Other antiviral drugs

    V.03.A.F   Drugs that reduce the toxicity of cytostatic therapy

    Pharmacodynamics:

    Enhances the synthesis of endogenous α-, β- and γ-interferons in intestinal epithelial cells, hepatocytes, neutrophils and T-lymphocytes, has no antigenic activity, does not cause hyperinterferonemia. Affects stem cells of red bone marrow, increases the formation of antibodies, restores the proportion of T-helpers / T-suppressors, reducing the degree of immunosuppression.

    Inhibits the transmission of virus-specific proteins in infected cells, stopping the reproduction of viruses. It is active against various viral infections, including herpes and influenza.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed up to 20% in the gastrointestinal tract. The maximum concentration of endogenous interferon in the blood plasma is reached after 48 hours. In the intestines - after 4 hours. The connection with plasma proteins is 37%, with lipids 47%.

    It is not metabolized or cumulated. Does not penetrate the blood-brain barrier.

    The half-life is 48 hours. Elimination with feces (90%) and kidneys (10%).

    Indications:

    It is used for the treatment of herpetic infection in the complex therapy of respiratory and urogenital chlamydiosis, is used for the prevention and treatment of influenza and acute respiratory viral infections.

    ICD-10

    I.A50-A64.A60   Anogenital herpetic viral infection [herpes simplex]

    XVI.P35-P39.P35.2   Congenital infection caused by the herpes simplex virus [herpes simplex]

    X.J00-J06   Acute respiratory infections of the upper respiratory tract

    X.J10-J18.J10   Influenza caused by an identified influenza virus

    Contraindications:

    Individual intolerance, children up to 3 years.

    Carefully:

    Severe kidney failure.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Use in children

    Treatment of acute respiratory viral infection and influenza from 3 to 6 years: 1 tablet 2 times a day for the first 2 days, then 1 tablet 1 time per day, course for 4 days. The course dose is 6 tablets.

    From 6 years: 1 tablet 3 times a day for the first 2 days, then 1 tablet 2 times a day, course for 4 days.The course dose is 10 tablets.

    Prevention of acute respiratory viral infection and influenza in children from 3 years: 1 tablet once a day for 2 days, after a break of 5 days, a repeated cycle is carried out. Preventive course: from 1 week to several months, depending on epidemiological tension.

    Adults

    Treatment of ARVI and influenza: 2 tablets 3 times a day for the first 2 days, then 1 tablet 3 times a day, course for 4 days. The course dose is 18 tablets.

    Prevention of acute respiratory viral infection and influenza: 2 tablets once a day for 2 days, after a break of 5 days, a repeated cycle is performed. Preventive course: from 1 week to several months, depending on epidemiological tension.

    The highest daily dose: 1 tablet; on the course - 18 tablets for 4 days.

    The highest single dose: 2 tablets.

    Side effects:

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Compatible with the drugs of all groups.

    Special instructions:

    When taken in doses exceeding therapeutic, the development of a short-term depletion of immunocompetent cells is possible.

    Instructions
    Up